USD
+$0.00
(+0.00%
)At Close (As of Dec 15, 2025)
$257.86M
Market Cap
-
P/E Ratio
-0.26
EPS
$9.92
52 Week High
$4.68
52 Week Low
HEALTHCARE
Sector
| Field | Value (USD) |
|---|---|
| Gross Profit | $44M |
| Total Revenue | $48M |
| Cost Of Revenue | $3.2M |
| Costof Goods And Services Sold | $3.2M |
| Operating Income | $2.6M |
| Selling General And Administrative | $23M |
| Research And Development | $307K |
| Operating Expenses | $42M |
| Investment Income Net | - |
| Net Interest Income | -$2.5M |
| Interest Income | $1.7M |
| Interest Expense | $4.1M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $800K |
| Income Before Tax | -$71K |
| Income Tax Expense | $365K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$436K |
| Comprehensive Income Net Of Tax | - |
| Ebit | $4M |
| Ebitda | $4.8M |
| Net Income | -$436K |
| Field | Value (USD) |
|---|---|
| Total Assets | $45M |
| Total Current Assets | $44M |
| Cash And Cash Equivalents At Carrying Value | $27M |
| Cash And Short Term Investments | $27M |
| Inventory | $1.1M |
| Current Net Receivables | $13M |
| Total Non Current Assets | $822K |
| Property Plant Equipment | - |
| Accumulated Depreciation Amortization Ppe | - |
| Intangible Assets | - |
| Intangible Assets Excluding Goodwill | - |
| Goodwill | - |
| Investments | - |
| Long Term Investments | - |
| Short Term Investments | - |
| Other Current Assets | $3.5M |
| Other Non Current Assets | - |
| Total Liabilities | $51M |
| Total Current Liabilities | $6.9M |
| Current Accounts Payable | $3.2M |
| Deferred Revenue | - |
| Current Debt | - |
| Short Term Debt | $2K |
| Total Non Current Liabilities | $44M |
| Capital Lease Obligations | $2K |
| Long Term Debt | $19M |
| Current Long Term Debt | - |
| Long Term Debt Noncurrent | - |
| Short Long Term Debt Total | $19M |
| Other Current Liabilities | $3.7M |
| Other Non Current Liabilities | - |
| Total Shareholder Equity | -$5.9M |
| Treasury Stock | - |
| Retained Earnings | -$220M |
| Common Stock | $146M |
| Common Stock Shares Outstanding | $27M |
| Field | Value (USD) |
|---|---|
| Gross Profit | $44M |
| Total Revenue | $48M |
| Cost Of Revenue | $3.2M |
| Costof Goods And Services Sold | $3.2M |
| Operating Income | $2.6M |
| Selling General And Administrative | $23M |
| Research And Development | $307K |
| Operating Expenses | $42M |
| Investment Income Net | - |
| Net Interest Income | -$2.5M |
| Interest Income | $1.7M |
| Interest Expense | $4.1M |
| Non Interest Income | - |
| Other Non Operating Income | - |
| Depreciation | - |
| Depreciation And Amortization | $800K |
| Income Before Tax | -$71K |
| Income Tax Expense | $365K |
| Interest And Debt Expense | - |
| Net Income From Continuing Operations | -$436K |
| Comprehensive Income Net Of Tax | - |
| Ebit | $4M |
| Ebitda | $4.8M |
| Net Income | -$436K |
Sector: HEALTHCARE
Industry: BIOTECHNOLOGY
Fennec Pharmaceuticals Inc. is a cutting-edge biopharmaceutical company headquartered in Research Triangle Park, North Carolina, dedicated to developing innovative therapies for cancer with a focus on pediatric patients. The company's lead product, Pedmark, is a novel treatment aimed at preventing chemotherapy-induced ototoxicity, representing a significant advancement in supportive care for young cancer patients. With a commitment to enhancing the quality of life for its patients, Fennec is well-positioned to address critical unmet medical needs in oncology, both domestically and internationally, thereby establishing itself as a key player in the biopharmaceutical sector.